EstechPharma Co. Ltd
EstechPharma Co., Ltd. manufactures and sells pharmaceuticals products. It also offers raw materials, such as RBM and PLK. The company was formerly known as Estech Chemical and changed its name to EstechPharma Co., Ltd. in January 2001. EstechPharma Co., Ltd. was founded in 1996 and is headquartered in Hwaseong-si, South Korea.
EstechPharma Co. Ltd (041910) - Net Assets
Latest net assets as of September 2025: ₩134.31 Billion KRW
Based on the latest financial reports, EstechPharma Co. Ltd (041910) has net assets worth ₩134.31 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩192.01 Billion) and total liabilities (₩57.70 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩134.31 Billion |
| % of Total Assets | 69.95% |
| Annual Growth Rate | 5.97% |
| 5-Year Change | 15.43% |
| 10-Year Change | 78.27% |
| Growth Volatility | 6.62 |
EstechPharma Co. Ltd - Net Assets Trend (2013–2024)
This chart illustrates how EstechPharma Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for EstechPharma Co. Ltd (2013–2024)
The table below shows the annual net assets of EstechPharma Co. Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩128.58 Billion | +11.20% |
| 2023-12-31 | ₩115.63 Billion | -0.39% |
| 2022-12-31 | ₩116.09 Billion | -5.85% |
| 2021-12-31 | ₩123.30 Billion | +10.69% |
| 2020-12-31 | ₩111.39 Billion | +8.44% |
| 2019-12-31 | ₩102.72 Billion | +15.09% |
| 2018-12-31 | ₩89.25 Billion | +8.34% |
| 2017-12-31 | ₩82.38 Billion | +6.41% |
| 2016-12-31 | ₩77.42 Billion | +7.34% |
| 2015-12-31 | ₩72.13 Billion | -5.08% |
| 2014-12-31 | ₩75.99 Billion | +11.81% |
| 2013-12-31 | ₩67.96 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to EstechPharma Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8584267536000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩85.84 Billion | 66.76% |
| Common Stock | ₩6.75 Billion | 5.25% |
| Other Components | ₩35.99 Billion | 27.99% |
| Total Equity | ₩128.58 Billion | 100.00% |
EstechPharma Co. Ltd Competitors by Market Cap
The table below lists competitors of EstechPharma Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Independent Bond
CO:IIVBON
|
$50.99 Million |
|
QUADPACK INDUSTRIES EO 1
F:4VP
|
$50.99 Million |
|
Wir Asia Tbk PT
JK:WIRG
|
$50.99 Million |
|
Bygg Partner i Dalarna Holding AB
ST:BYGGP
|
$51.00 Million |
|
Pepkor Holdings Ltd
JSE:PPH
|
$50.99 Million |
|
Eastside Distilling, Inc.
NASDAQ:BLNE
|
$50.97 Million |
|
UNICOMMERCE ESOLUTIONS LIMITED
NSE:UNIECOM
|
$50.96 Million |
|
Farcent Enterprise Co Ltd
TW:1730
|
$50.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EstechPharma Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 115,632,727,350 to 128,582,659,930, a change of 12,949,932,580 (11.2%).
- Net income of 3,947,862,010 contributed positively to equity growth.
- Dividend payments of 1,168,000,600 reduced retained earnings.
- Share repurchases of 10,149,779,060 reduced equity.
- New share issuances of 10,149,779,050 increased equity.
- Other factors increased equity by 10,170,071,180.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩3.95 Billion | +3.07% |
| Dividends Paid | ₩1.17 Billion | -0.91% |
| Share Repurchases | ₩10.15 Billion | -7.89% |
| Share Issuances | ₩10.15 Billion | +7.89% |
| Other Changes | ₩10.17 Billion | +7.91% |
| Total Change | ₩- | 11.20% |
Book Value vs Market Value Analysis
This analysis compares EstechPharma Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.89x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.25x to 0.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩6860.74 | ₩8570.00 | x |
| 2017-12-31 | ₩7127.86 | ₩8570.00 | x |
| 2018-12-31 | ₩7641.34 | ₩8570.00 | x |
| 2019-12-31 | ₩8794.54 | ₩8570.00 | x |
| 2020-12-31 | ₩9537.09 | ₩8570.00 | x |
| 2021-12-31 | ₩10556.39 | ₩8570.00 | x |
| 2022-12-31 | ₩9939.13 | ₩8570.00 | x |
| 2023-12-31 | ₩9900.05 | ₩8570.00 | x |
| 2024-12-31 | ₩9679.99 | ₩8570.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently EstechPharma Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.62%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.05x
- Recent ROE (3.07%) is below the historical average (5.22%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 5.45% | 8.76% | 0.40x | 1.54x | ₩-3.09 Billion |
| 2014 | 11.24% | 19.31% | 0.39x | 1.51x | ₩940.02 Million |
| 2015 | -1.21% | -1.93% | 0.49x | 1.27x | ₩-8.08 Billion |
| 2016 | 5.36% | 9.56% | 0.45x | 1.26x | ₩-3.59 Billion |
| 2017 | 3.31% | 7.13% | 0.40x | 1.15x | ₩-5.51 Billion |
| 2018 | 7.38% | 16.34% | 0.41x | 1.10x | ₩-2.34 Billion |
| 2019 | 14.82% | 32.76% | 0.40x | 1.13x | ₩4.96 Billion |
| 2020 | 9.84% | 17.87% | 0.50x | 1.11x | ₩-182.46 Million |
| 2021 | 5.58% | 11.38% | 0.45x | 1.09x | ₩-5.46 Billion |
| 2022 | -5.48% | -10.26% | 0.50x | 1.07x | ₩-17.97 Billion |
| 2023 | 3.31% | 5.95% | 0.53x | 1.05x | ₩-7.74 Billion |
| 2024 | 3.07% | 6.62% | 0.44x | 1.05x | ₩-8.91 Billion |
Industry Comparison
This section compares EstechPharma Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $93,185,141,571
- Average return on equity (ROE) among peers: -11.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EstechPharma Co. Ltd (041910) | ₩134.31 Billion | 5.45% | 0.43x | $50.99 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.69 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $94.65 Billion | 9.66% | 0.53x | $57.77 Million |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $37.82 Million |
| Sam-A Pharm. Co. Ltd (009300) | $148.92 Billion | 6.63% | 0.09x | $21.27 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $257.20 Billion | 4.73% | 0.21x | $50.06 Million |
| WooGene B&G Co. Ltd (018620) | $26.51 Billion | -25.02% | 1.26x | $10.61 Million |
| Oscotec Inc (039200) | $28.83 Billion | -91.10% | 0.70x | $890.75 Million |
| Komipharm International Co. Ltd (041960) | $93.39 Billion | -15.32% | 0.50x | $237.27 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $40.83 Billion | 8.91% | 0.29x | $20.48 Million |